How many drugs treat beta Thalassemia?

Drug Landscape tracks 6 marketed treatments for beta Thalassemia (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/beta-thalassemia.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-09 · How we verify

beta Thalassemia — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

beta Thalassemia (disease) competitive landscape: 6 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

6 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating beta Thalassemia, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Reblozyl	LUSPATERCEPT	Celgene Corp	Erythroid Maturation Agent [EPC]	Growth/differentiation factor 11	2019-01-01
Ferriprox	DEFERIPRONE	Chiesi	Iron Chelator [EPC]	Deoxyhypusine hydroxylase	2011-01-01
Exjade	DEFERASIROX	Novartis	Iron Chelator [EPC]	Flavin reductase (NADPH)	2005-01-01
Reblozyl	Reblozyl	EuroBloodNet Association		Growth/differentiation factor 11, Growth/differentiation factor 8
Exjade	Exjade	DisperSol Technologies, LLC		Flavin reductase (NADPH), Lysine-specific demethylase 5A
REBLOZYL	LUSPATERCEPT-AAMT	CELGENE CORP	Erythroid Maturation Agent [EPC]	Growth/differentiation factor 11, Growth/differentiation factor 8

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

CELGENE CORP · 1 drug in beta Thalassemia
Celgene Corp · 1 drug in beta Thalassemia
Chiesi · 1 drug in beta Thalassemia
DisperSol Technologies, LLC · 1 drug in beta Thalassemia
EuroBloodNet Association · 1 drug in beta Thalassemia
Novartis · 1 drug in beta Thalassemia

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in beta Thalassemia:

Cite this brief

Drug Landscape (2026). beta Thalassemia — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/beta-thalassemia. Accessed 2026-06-09.

beta Thalassemia full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing